Ann: Cholesterol-Lowering Program Update, page-50

ahh yea fair call. Still doesn’t change the need for a cap raise, maybe the timing by a quarter. Mgmt will be pushing hard for a replacement for cholesterol, even if they aren’t in P1 until H2 next year just to give some hope to punters. It has been long known that the market only ascribed value to cholesterol, that can be seen by the SP at circa cash backing ( I.e TBI has not been ascribed any value).. based on other P1 trials in the TBI space, if they can get safety through P1 I’d think we have a $50-$100m mkt cap.. hopefully I snag a top up today..